Britain crashes out of favor with US pharmaceutical executives

The biotech industry is a pillar of the knowledge economy, with governments around the world investing heavily to attract capital and develop a highly skilled workforce. Britain has historically enjoyed privileged status for US companies looking to expanding into Europe, offering a common language, world-class talent, a reputation of excellence in clinical research and easy access to the European medicines regulatory agency.

We surveyed C-suite biotech executives in pre-eminent US companies. How do they see the European pharmaceutical market changing? Is it now overshadowed by the rapidly expanding Asian market? How is Brexit impacting Britain’s status as a launchpad into Europe?

The results of our research are summarized in the infographic below.

US Pharma executive opinions on Europe and Brexit

Case Studies

For more information on how we can assist your biotech or pharmaceutical project, please reach out.

.custom-post-pagination {display: none;}